BioCentury
ARTICLE | Top Story

Amgen boosts revenue guidance ahead of Repatha

April 22, 2015 2:19 AM UTC

Amgen Inc. (NASDAQ:AMGN) boosted its revenue guidance for 2015 as it prepares to launch products in its new cardiovascular business and anticipates regulatory actions in its cancer franchise.

EVP of R&D Sean Harper said during Amgen's 1Q15 earnings call Tuesday that this month's launch of chronic heart failure drug Corlanor ivabradine gives the company an opportunity to build a presence in the U.S. cardiovascular market ahead of its anticipated launch of Repatha evolocumab to treat high cholesterol. ...